PureTech subsidiary licences microbiome-based therapy

By

Sharecast News | 05 May, 2017

PureTech Health subsidiary Commense Inc has licensed a microbiome-based therapy to prevent asthma and other allergic diseases from the University of British Columbia.

Last news

London close: Stocks rise as US PCE inflation slows
Rightmove tells shareholders to 'take no action' over £6.2bn REA offer
Learning Technologies 'minded to recommend' takeover bid from General Atlantic
Director dealings: Wizz Air director makes share purchase
FTSE 100 movers: Prudential rallies again; Flutter gives back some gains